Cargando…
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
BACKGROUND: Human African trypanosomiasis (HAT) is an important public health problem in sub-Saharan Africa, affecting hundreds of thousands of individuals. An urgent need exists for the discovery and development of new, safe, and effective drugs to treat HAT, as existing therapies suffer from poor...
Autores principales: | Jacobs, Robert T., Nare, Bakela, Wring, Stephen A., Orr, Matthew D., Chen, Daitao, Sligar, Jessica M., Jenks, Matthew X., Noe, Robert A., Bowling, Tana S., Mercer, Luke T., Rewerts, Cindy, Gaukel, Eric, Owens, Jennifer, Parham, Robin, Randolph, Ryan, Beaudet, Beth, Bacchi, Cyrus J., Yarlett, Nigel, Plattner, Jacob J., Freund, Yvonne, Ding, Charles, Akama, Tsutomu, Zhang, Y.-K., Brun, Reto, Kaiser, Marcel, Scandale, Ivan, Don, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125149/ https://www.ncbi.nlm.nih.gov/pubmed/21738803 http://dx.doi.org/10.1371/journal.pntd.0001151 |
Ejemplares similares
-
Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis
por: WRING, STEPHEN, et al.
Publicado: (2014) -
Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT)
por: Akama, Tsutomu, et al.
Publicado: (2018) -
2,4-Diaminopyrimidines as Potent Inhibitors of Trypanosoma brucei and Identification of Molecular Targets by a Chemical Proteomics Approach
por: Mercer, Luke, et al.
Publicado: (2011) -
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides
por: Thompson, Andrew M., et al.
Publicado: (2018) -
DNDI-6148: A Novel
Benzoxaborole Preclinical Candidate
for the Treatment of Visceral Leishmaniasis
por: Mowbray, Charles E., et al.
Publicado: (2021)